Ultragenyx Pharmaceutical Inc. - Common Stock (RARE)
40.87
0.00 (0.00%)
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of rare genetic disorders
The company specializes in creating novel treatments targeting serious diseases caused by genetic mutations, particularly those that affect critical metabolic pathways. With a strong emphasis on research and development, Ultragenyx strives to bring hope and improved quality of life to patients living with rare conditions by harnessing cutting-edge science and technology to address unmet medical needs.
Ultragenyx forecasts 2024 revenue above estimates, highlights confidence in setrusumab trial progress, and outlines plans for regulatory filings in 2025.
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.
Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety profile is favorable. Phase 3 study planned for 2025.
The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical over the use of HeLa cells taken without her consent in the 1950s. A Maryland federal court ruled against Ultragenyx's motion to dismiss, allowing the case to continue.
RARE stock results show that Ultragenyx Pharmaceutical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also fell, dropping, 1.14% to 5,065.04.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQRARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
